Point-of-Care Diagnostic Test for Beta-Thalassemia
Biosensors · 02.02.2024 · 14 (2) · 83
DOI: 10.3390/bios14020083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, online erschienen am 02.02.2024. Verfasst von Ran An und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: beta-Thalassemia, Antelopes, Hemoglobinopathies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Heart, Lung, and Blood Institute Small Business Innovation Research Program.
Abstract (Originalsprache)
Hemoglobin (Hb) disorders are among the most common monogenic diseases affecting nearly 7% of the world population. Among various Hb disorders, approximately 1.5% of the world population carries β-thalassemia (β-Thal), affecting 40,000 newborns every year. Early screening and a timely diagnosis are essential for β-thalassemia patients for the prevention and management of later clinical complications. However, in Africa, Southern Europe, the Middle East, and Southeast Asia, where β-thalassemia is most prevalent, the diagnosis and screening for β-thalassemia are still challenging due to the cost and logistical burden of laboratory diagnostic tests. Here, we present Gazelle, which is a paper-based microchip electrophoresis platform that enables the first point-of-care diagnostic test for β-thalassemia. We evaluated the accuracy of Gazelle for the β-Thal screening across 372 subjects in the age range of 4–63 years at Apple Diagnostics lab in Mumbai, India. Additionally, 30 blood samples were prepared to mimic β-Thal intermediate and β-Thal major samples. Gazelle-detected levels of Hb A, Hb F, and Hb A2 demonstrated high levels of correlation with the results reported through laboratory gold standard high-performance liquid chromatography (HPLC), yielding a Pearson correlation coefficient = 0.99. This ability to obtain rapid and accurate results suggests that Gazelle may be suitable for the large-scale screening and diagnosis of β-Thal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH 44106, USA.
- Department of Biomedical Engineering, University of Houston, Houston, TX 77004, USA.
- Department of Biomedical Sciences, University of Houston, Houston, TX 77004, USA.
- HemexHealth, Inc., Portland, OR 97239, USA.
- Plasma Lab, Jalgaon 425001, India.
- Apple Diagnostics Lab, Ghatkopar, Mumbai 400077, India.
ORCID-Profile: Alireza Avanaki, Umut A Gurkan
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- National Heart, Lung, and Blood Institute Small Business Innovation Research Program
- National Center for Complementary & Integrative Health
- National Institute of Diabetes and Digestive and Kidney Diseases Small Business Innovation Research Program
- NHLBI
Zitieren
APA
An, R., Avanaki, A., Thota, P., Nemade, S., Mehta, A., & Gurkan, U. A. (2024). Point-of-Care Diagnostic Test for Beta-Thalassemia. Biosensors, 14(2), 83. https://doi.org/10.3390/bios14020083
Vancouver
An R, Avanaki A, Thota P, Nemade S, Mehta A, Gurkan UA. Point-of-Care Diagnostic Test for Beta-Thalassemia. Biosensors. 2024;14(2):83. doi:10.3390/bios14020083
BibTeX
@article{An2024,
author = {An, Ran and Avanaki, Alireza and Thota, Priyaleela and Nemade, Sai and Mehta, Amrish and Gurkan, Umut A},
title = {Point-of-Care Diagnostic Test for Beta-Thalassemia},
journal = {Biosensors},
year = {2024},
volume = {14},
number = {2},
pages = {83},
doi = {10.3390/bios14020083}
}
EUVIMED